Vaping's Toll: Hospitalizations Rise

Vaping has been linked to a range of health issues, including lung disease, heart disease, and fetal developmental problems. In 2019, the CDC began investigating a surge in hospitalizations tied to vaping products, with patients presenting respiratory symptoms such as shortness of breath, cough, and chest pain. This condition, dubbed EVALI (E-cigarette or Vaping product use-associated lung injury), had led to over 2,800 hospitalizations and 68 deaths by February 2020. The primary cause of EVALI is believed to be vitamin E acetate, a chemical added to some THC-containing vaping products. However, other chemicals in both THC and non-THC products may also contribute to the illness. While vaping is often viewed as a less harmful alternative to tobacco use, it can lead to serious health consequences, including hospitalizations and deaths.

The number of hospitalizations due to vaping

Vaping has been linked to severe lung disease, including e-cigarette, or vaping, product use-associated lung injury (EVALI). In 2020, there were more than 2,800 cases of e-cigarette users who required hospitalization due to EVALI, with 68 resulting in death. This condition is characterised by respiratory symptoms such as shortness of breath, cough, and chest pain.

The median age of patients hospitalised with EVALI was 24 years, with a range of 13–85 years. It is important to note that 57% of these patients reported using nicotine-containing products, while 14% reported exclusive use of nicotine-containing products. Additionally, 50% of patients who reported using THC-containing products disclosed their product source, with 16% acquiring them from commercial sources and 78% from informal sources such as family, friends, or online dealers.

The diagnosis of EVALI can be challenging as its symptoms resemble those of other respiratory illnesses like pneumonia and influenza. Treatment for EVALI typically involves medications to reduce lung inflammation, respiratory support, supplemental oxygen, and antibiotics or antivirals while awaiting diagnostic results.

Furthermore, vaping has been associated with other health concerns, including worsening asthma and chronic obstructive pulmonary disease (COPD). The cost of treating COPD-related cases amounts to nearly $50 billion per year. Vaping devices contain nicotine, which can lead to addiction and increase cravings. Accidental exposure to e-cigarette liquids has also resulted in acute nicotine poisoning in both children and adults.

In summary, the number of hospitalizations due to vaping, specifically related to EVALI, was over 2,800 in 2020, with a median patient age of 24 years. The use of nicotine-containing and THC-containing products has been prominent among these cases, with treatment focusing on respiratory support and lung inflammation reduction. The health consequences of vaping extend beyond EVALI, impacting asthma, COPD, and poisoning cases, particularly in children.

EVALI diagnosis and treatment

EVALI, or e-cigarette or vaping product use-associated lung injury, is a serious health condition that emerged in the United States in 2019. It is characterised by symptoms such as cough, shortness of breath, chest pain, fever, and gastrointestinal issues like nausea and vomiting.

Diagnosis of EVALI can be challenging and complex due to its similar symptoms to other respiratory illnesses, such as pneumonia and the seasonal flu. There is no single test for EVALI, and it is often diagnosed through a process of elimination. Doctors will typically begin by asking patients about their use of e-cigarettes within the past three months and whether they vaped a product containing nicotine, THC, or both. A physical examination will assess respiratory function and overall health, and several diagnostic tests may be employed to confirm EVALI, including blood tests, imaging studies, and specialised procedures such as bronchoscopy.

The treatment for EVALI typically involves a combination of medications and supportive care:

• Corticosteroids: These are used to reduce inflammation in the lungs and throughout the body. It is recommended to start with a lower dose and gradually increase to prevent resistance and dependence on the medication.
• Supportive care: Patients may receive supplemental oxygen through a nasal cannula. In more severe cases, they may be placed on a mechanical ventilator or an extracorporeal membrane oxygenation machine.
• Antibiotics: These drugs may be administered while waiting for diagnostic test results as it can be difficult to distinguish EVALI from bacterial infections.
• Antivirals: These may be used, especially during the influenza season, as EVALI shares similar symptoms with some viral infections.

The prognosis for individuals diagnosed with EVALI varies based on the severity of the condition, the timeliness of treatment, early diagnosis, treatment adherence, and underlying health conditions. Many patients experience significant improvement with appropriate medical care, while others may face long-term respiratory issues. Lifestyle modifications, such as smoking cessation, are also crucial for recovery.

The dangers of vaping during pregnancy

Vaping has been linked to severe lung injuries, with over 2,800 people hospitalized and 68 deaths recorded as of February 2020. This condition, known as EVALI (E-cigarette or Vaping product use-associated lung injury), causes respiratory symptoms such as shortness of breath, cough, and chest pain. While the exact mechanism of how vaping contributes to lung injury is still being investigated, it is clear that vaping during pregnancy poses significant risks to both the mother and the developing fetus.

Firstly, nicotine, which is commonly found in vaping products, is highly addictive and can negatively impact fetal development. It can affect the developing brain and lungs of the fetus, increasing the risk of long-term harm. Additionally, some flavorings and additives in e-cigarettes may also be harmful to the mother and fetus, with studies identifying them as potential developmental toxicants.

Secondly, the aerosol produced by e-cigarettes contains harmful substances, including volatile organic compounds (VOCs) and heavy metals, which are known carcinogens. Exposure to these chemicals during pregnancy may increase the mother's risk of cancer and potentially impact fetal development. While the long-term effects of vaping on cancer incidence are still unknown, biomarkers of carcinogens have been found in higher concentrations in the urine of e-cigarette users compared to non-users.

Furthermore, the perception that vaping is a safer alternative to smoking during pregnancy may contribute to its increasing popularity among pregnant women. However, this belief is misleading, as vaping devices contain numerous toxic chemicals linked to lung disease, heart disease, and severe lung injury. The true balance between the benefits and risks of vaping remains unclear, and there is a pressing need for further studies to assess the potential risks to maternal and fetal health.

In summary, vaping during pregnancy can expose both the mother and fetus to harmful substances, increasing the risk of adverse health effects. While quitting smoking is challenging, it is essential to recognize that vaping is not a safe alternative during pregnancy. Pregnant women should seek approved methods of smoking cessation, such as counseling, to protect their health and the well-being of their developing fetus.

The link between vaping and lung disease

Vaping has been linked to lung disease, severe lung injury, and even death. E-cigarette, or vaping, product use-associated lung injury is also known as EVALI. As of February 2020, there have been over 2,800 cases of hospitalized EVALI patients, with 68 deaths caused by the condition. However, there has been a substantial drop in cases since they peaked in August and September of 2020.

The symptoms of EVALI include a host of respiratory issues, including shortness of breath, cough, and chest pain. Many patients with EVALI also experience nausea, vomiting, and diarrhea. EVALI is challenging to diagnose because its symptoms are similar to those of other respiratory illnesses, such as pneumonia and the seasonal flu virus. There is no single test for EVALI, so doctors must rule out other potential diseases and conditions through diagnostic tests and inquiries into the patient's vaping history.

The use of vaping products within the previous three months is a common factor among EVALI patients. The CDC reports that over 80% of hospitalized EVALI patients reported using vaping products containing THC, and nearly 80% of these patients obtained their vaping products from "informal sources" such as family, friends, dealers, or online sources. Vitamin E acetate, a chemical added to some THC-containing vaping products, has been strongly linked to the EVALI outbreak. However, evidence also suggests that other chemicals in both THC-containing and non-THC-containing products may contribute to EVALI.

The treatment for EVALI includes medications and respiratory support. Patients may receive corticosteroids to reduce lung inflammation and supplemental oxygen through a nasal cannula. In severe cases, mechanical ventilation or an extracorporeal membrane oxygenation machine may be necessary. Antibiotics and antivirals may also be administered due to the difficulty in distinguishing EVALI from bacterial and viral infections.

While the true balance between the benefits and risks of vaping remains uncertain, the cases of severe lung disease among vapers raise important questions about its safety. Vaping devices contain nicotine, an addictive substance that can increase cravings and affect the developing brain. Additionally, the aerosol from e-cigarettes contains harmful substances that can expose both users and bystanders to health risks. Furthermore, vaping can worsen existing respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).

The cost of vaping-related hospitalizations

Firstly, it's important to acknowledge the direct medical costs associated with vaping-related hospitalizations. Research published in the journal Tobacco Control estimated that the excess medical care costs among exclusive e-cigarette users totaled a staggering $1.3 billion annually in the United States. This equates to roughly $1,800 more per exclusive e-cigarette user compared to a non-tobacco user. The financial burden is even higher for dual or poly tobacco users (those who smoke and vape), with average excess medical care costs of $2,050 per person. These costs include hospital inpatient stays, emergency room visits, doctor appointments, and home health visits.

The costs of vaping-related hospitalizations also extend beyond the hospital walls. For individuals, there is the cost of lost productivity due to illness and time away from work or school. Additionally, individuals may face higher insurance premiums or out-of-pocket expenses not covered by insurance. In the case of severe or prolonged illness, there may be long-term care costs or expenses associated with disability accommodations.

Employers also bear a significant financial burden when their employees are hospitalized due to vaping-related illnesses. Absenteeism and reduced productivity among affected employees can result in substantial economic losses for businesses. Additionally, employers may face increased insurance premiums and expenses related to employee health benefits.

Lastly, society as a whole bears the cost of vaping-related hospitalizations through public health expenditures and the strain on healthcare resources. The impact of vaping-related illnesses goes beyond the individual and affects the well-being of communities. Furthermore, the social cost includes the potential for increased social welfare expenses if individuals are unable to work or require long-term support.

The human cost of vaping-related hospitalizations must also be considered. Vaping has been linked to severe lung injuries, known as EVALI (e-cigarette, or vaping product use-associated lung injury), which has resulted in deaths. As of February 2020, the CDC recorded over 2,800 hospitalizations due to EVALI, with 68 fatalities. The human toll of these hospitalizations includes not just the physical suffering of patients but also the mental and emotional distress experienced by them and their loved ones.

Frequently asked questions